ArticleBMC cancer2026
EVX2 methylation assay enables risk assessment of cervical cancer in high-risk HPV-infected individuals.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStratifying cancer risk in high-risk human papillomavirus (hr-HPV) infected individuals can effectively reduce colposcopy referrals and minimize invasive procedures. Current assay methods need to be improved and perfected.
methodsFour methylation markers (ZNF135, EVX2, MARCHF11, and UBD) were identified to discriminate cervical cancer (CC) from normal mucosal tissues through the analysis of TCGA/GEO cohorts. Subsequently, a specific methylation marker (EVX2) was further identified via immunohistochemical (IHC) assays and an extensive literature review. After validating the applicability of this technique for EVX2 methylation detection via MALDI-TOF mass spectrometry, a methylation model was constructed based on the selected markers in a retrospective cohort of cervical exfoliated cells (n = 104) and validated in an independent cohort (n = 22) using the identical technique and random forest algorithm. The diagnostic performance was systematically compared with LCT and high-oncogenicity HPV16/18 testing.
resultsFour methylation markers (ZNF135, EVX2, MARCHF11, and UBD) were identified that could discriminate CC from normal squamous epithelia. Among these markers, EVX2 was further pinpointed as the key candidate based on gene expression and literature review. A diagnostic model constructed via EVX2 methylation status exhibited robust diagnostic performance in differentiating patients with squamous intraepithelial lesion (SIL) or CC from healthy normal controls, and its diagnostic efficacy was significantly superior to that of LCT and HPV16/18 assays (AUC: 0.95 vs. 0.85 for LCT and 0.57 for HPV16/18 testing). This superiority was more pronounced in detecting HSIL and CC, with a detection rate of 96.97% versus 57.14% (LCT) and 37.5% (HPV16/18 testing). Subsequent analyses of TCGA databases further validated the diagnostic value of EVX2 methylation in CC.
conclusionsEVX2 methylation detection via MALDI-TOF mass spectrometry reliably discriminates normal squamous epithelium from HSIL and above cervical malignant lesions, and may serve as a rapid, non-invasive, and promising tool for cancer-risk screening and triage in hr-HPV-positive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.